Why are Genentech cancer researchers worried?

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. 

A busy end of this week! Today, we see an approval for a new type of schizophrenia drug, we see the Biden administration back off a Medicaid proposal, and delve into what Pfizer’s withdrawal of a sickle cell drug means.

What the withdrawal of Pfizer’s sickle cell drug means

A day after Pfizer pulled its sickle cell drug Oxbryta from the market due to safety concerns, patients and advocates are expressing shock.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In